Experienced in Toxocariasis

Nobuo Ohta

Toyota Central R&D Labs. Inc, 41-1, 
Nagakute, JP 
Experienced in Toxocariasis
Toyota Central R&D Labs. Inc, 41-1, 
Nagakute, JP 
OverviewLocationsClinical Research

Overview

Nobuo Ohta practices in Nagakute, Japan. Mr. Ohta is rated as an Experienced expert by MediFind in the treatment of Toxocariasis. His top areas of expertise are Branchial Cleft Cyst, Allergic Rhinitis, Perichondritis, Myringotomy, and Thyroidectomy.

His clinical research consists of co-authoring 153 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Toxocariasis.

Gender
Male

Locations

Toyota Central R&D Labs. Inc, 41-1, Nagakute, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Randomised, Double-blind, Placebo Controlled, Parallel Group Phase III Study to Assess the Clinical Efficacy and Safety of 100 mg SC Mepolizumab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) / Eosinophilic Chronic Rhinosinusitis (ECRS) MERIT: Mepolizumab in Eosinophilic Chronic RhinosinusITis Study
A Randomised, Double-blind, Placebo Controlled, Parallel Group Phase III Study to Assess the Clinical Efficacy and Safety of 100 mg SC Mepolizumab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) / Eosinophilic Chronic Rhinosinusitis (ECRS) MERIT: Mepolizumab in Eosinophilic Chronic RhinosinusITis Study
Enrollment Status: Completed
Publish Date: November 25, 2024
Intervention Type: Drug
Study Drugs: Mepolizumab, Standard of Care
Study Phase: Phase 3

153 Total Publications

Expressions of VEGF, Vasohibin-1, and Vasohibin-2 in Benign Parotid Gland Tumors.
Expressions of VEGF, Vasohibin-1, and Vasohibin-2 in Benign Parotid Gland Tumors.
Journal: The Tohoku journal of experimental medicine
Published: October 01, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Ohta's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 42 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile